Mitsuya Ito

Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study

Norikazu Masuda, Hiroyuki Yasojima, Hiroko Bando, T. Yamanaka et autres

To investigate long-term outcomes for triple‑negative breast cancer (TNBC) patients enrolled in JBCRG-22. TNBC (cT1c–T3, cN0–1, M0) patients were stratified by homologous recombination deficiency (HRD) and germline BRCA mutation (gBRCAm) status. Group A patients (aged < 65 years with HRD-positive tumors, or …

jp (code pays fourni par la source)

Radiofrequency Ablation for Early Stage Breast Cancer as a Potential Alternative to Partial Mastectomy: 5-Year Results from the Multiple-Center, Single-Arm, Phase 3 RAFAELO Study (NCCH1409)

Takayuki Kinoshita, Shin Takayama, Tomomi Fujisawa, Kenichi Watanabe et autres

jp (code pays fourni par la source)

Overall survival and subsequent therapy patterns in Japanese patients with ER+/HER2− advanced breast cancer treated with palbociclib plus letrozole in the first-line setting: a final analysis

Masato Takahashi, Hiroyuki Yasojima, Tomofumi Osako, Kenichi Inoue et autres

BACKGROUND: An open-label, single-arm, multicenter Japanese phase 2 study (J-Ph2) found first-line palbociclib plus letrozole to be effective and tolerable in postmenopausal Japanese women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer (ABC), but overall survival (OS) data …

jp, ch (code pays fourni par la source)

221P Long-term outcomes of eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer: Results of the randomized JBCRG-22 study

Hiroyuki Yasojima, N Masuda, Hideaki Bando, Takashi Yamanaka et autres

We investigated the clinical usefulness of eribulin (E)-based neoadjuvant chemotherapy in patients (pts) with triple-negative breast cancer (TNBC); pts who received E-based regimens showed pathological complete response (pCR) rates of 19–45%, with less neurotoxicity (https://doi.org/10.1007/s10549-021-06184-w). Here, we report 5-yr survival outcomes.

jp (code pays fourni par la source)

Accumulation of CD56+ CD16- Natural Killer Cells in Response to Preoperative Chemotherapy for Breast Cancer

Ryungsa Kim, Ami Kawai, Megumi Wakisaka, Mika Shimoyama et autres

Background: The activation of the antitumor immune responses of T cells and natural killer (NK) cells is important to induce breast tumor shrinkage via preoperative chemotherapy. We evaluated how antitumor immune responses contribute to the effects of such therapy. Methods: Forty-three patients …

jp (code pays fourni par la source)

Radiofrequency ablation without excision for breast cancer: 5-year results of ipsilateral breast tumor recurrence-free survival in the RAFAELO study (NCCH1409).

Takayuki Kinoshita, Shin Takayama, Masato Takahashi, Tomomi Fujisawa et autres

578 Background: The RAFAELO study is designed to evaluate the safety and efficacy of breast radiofrequency ablation, enabling women between 20 and 79 years of age with small breast cancers to benefit from a nonsurgical treatment and to avoid the associated surgical …

jp (code pays fourni par la source)

Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)

Toshimi Takano, Norikazu Masuda, Mitsuya Ito, Kenichi Inoue et autres

PURPOSE: The randomized phase 2 Neo-peaks study examined usefulness of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) following docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) as compared with the standard TCbHP regimen. We previously reported that pCR rate after neoadjuvant …

jp (code pays fourni par la source)

Abstract PO2-06-06: Effectiveness and prognostic predictors of primary systemic therapy for de-novo Stage IV breast cancer - Supplementary analysis of JCOG1017 PRIM-BC

Tadahiko Shien, Akihiko Shimomura, Makoto Ishitobi, Kiyo Tanaka et autres

Abstract Background The optimal choice of drug is important in treating metastatic breast cancer, and the efficacy of the drug should be determined early, especially in cases of progression. On the other hand, untreated de novo Stage IV (dnST-IV) patients are expected …

jp, es, us, se (code pays fourni par la source)

Abstract PO1-05-05: Overall survival (OS) and subsequent therapy patterns in Japanese patients with HR+/HER2− advanced breast cancer (ABC) treated with palbociclib (PAL) plus letrozole (LET) in first-line setting (1L)

Masato Takahashi, Tomofumi Osako, Hiroyuki Yasojima, Kenichi Inoue et autres

Abstract Background: PAL is a first-in-class cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) for the treatment of HR+/HER2− ABC. In PALOMA-2 study, PAL plus LET demonstrated a numerically, not statistically significant, prolonged OS versus placebo plus LET (53.9 vs 51.2 months; HR, 0.956; 95% …

jp, us (code pays fourni par la source)

Efficacy and safety of pegfilgrastim biosimilar MD ‐110 in patients with breast cancer receiving chemotherapy: Single‐arm phase III

Toshimi Takano, Mitsuya Ito, Takayuki Kadoya, Tomofumi Osako et autres

Abstract Introduction Pegfilgrastim is indicated to decrease the incidence of chemotherapy‐induced febrile neutropenia. It is the first granulocyte‐colony stimulating factor approved for prophylactic use regardless of carcinoma type and is marketed in Japan as G‐LASTA (Kyowa Kirin Co., Ltd., Tokyo, Japan). MD‐110 …

jp (code pays fourni par la source)

A randomized controlled trial comparing primary tumor resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group study JCOG1017.

Tadahiko Shien, Fumikata Hara, Kenjiro Aogi, Yasuhiro Yanagita et autres

523 Background: The possibility of primary tumor resection (PTR) improving the survival of de-novo Stage IV breast cancer (dn-StIV BC) patients has been evaluated by several prospective studies but remains controversial. We designed this phase 3 trial (JCOG1017) comparing with/without primary dissection …

jp (code pays fourni par la source)

Abstract P5-02-48: Identifying immune-related predictive factors for paclitaxel + bevacizumab therapy in patients with HER2-negative advanced breast cancer- A multicenter retrospective study

Junichiro Watanabe, Takashi Sugino, Koji Muramatsu, Satoshi Morita et autres

Abstract Background: In IMpassion 130 trial, programmed death-ligand 1 (PD-L1) expression was seen in about 40% of participated patients with triple negative advanced breast cancer (TN-ABC) [Schmid, 2018, N Engl J Med], however, actual situation of PD-L1 expression in patients HER2-negative ABC …

jp (code pays fourni par la source)